证券日报网讯三元生物11月25日发布公告，在公司回答调研者提问时表示，公司围绕功能糖的产业化应 用，始终坚持以客户需求为导向，积极推进新品市场开拓。在阿洛酮糖方面，泰莱等多家美国客户对阿 洛酮糖的需求较为旺盛，澳大利亚和东南亚市场的接受度也开始增加。国内目前拥有阿洛酮糖生产许可 证并具备实际产能的厂家较少，为公司抢占市场先机创造了有利条件。塔格糖方面，日本下游企业正在 加速布局，已有客户前来公司调研产能与质量体系，以确保其终端产品的原料供应稳定性。此外，有日 本知名企业计划开发含甘露糖的食品，正在研究以公司产品为基础推动甘露糖在日本的法规注册。上述 部分合作仍处于沟通与论证阶段，公司将继续在合规前提下稳步推进新品落地。 （文章来源：证券日报） ...

山东三元生物科技股份有限公司 投资者关系活动记录表 编号：2025-003 |  | 特定对象调研 分析师会议 | □ | | | --- | --- | --- | --- | | □ 投资者关系活动 | 媒体采访 | □ | 业绩说明会 | | □ 类别 | 新闻发布会 | □ | 路演活动 | | □ | 现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | | | | 上海万纳私募基金管理有限公司杨君弈；中信建投证券股份有限 | | | | | 公司夏克扎提·努力木、杨骥、高畅；和谐健康保险股份有限公 | | | | | 司毛一鹏；平安理财有限责任公司芶思雨；招银国际资产管理有 | | | | | 限公司张慎平；华夏理财有限责任公司何煦；广东正圆私募基金 | | | | | 管理有限公司侯昭慧；中信建投经管委财富管理部客户裘峥、赖 | | | | | 昕；北京坤溪私募基金管理有限公司李任翾；长安汇通集团有限 | | | | | 责任公司李郑浩峰；博道基金管理有限公司陈磊；上海渊泓投资 | | | | | 管理有限公司顾屹泉；淳厚基金管理有限公司顾伟；深圳安瑞置 | | | | 参 ...

中信证券研报表示，2026年，周期和成长仍然是驱动农业板块的主要投资逻辑。周期视角来看，在市场 化亏损以及行政去产能合力下，2025年四季度以及2026年上半年产能去化或呈现加速态势，2026年猪价 或震荡上行。此外，畜禽产业链上持续推荐经营能力领先、穿越周期的公司。种子种植领域推荐品种资 源优势强劲的公司。成长视角来看，宠物板块国内需求稳健，国货势头强劲，2026年下半年或继续迎业 绩高增。果蔬种植方面，预计蓝莓红利仍将持续。重点推荐种植面积持续增长、种植效率持续提升、品 牌和渠道持续进步、出海节奏加快的蓝莓龙头。功能糖领域迎超级代糖大单品。 ...

中信证券研报认为，2026年，周期和成长仍然是驱动农业板块主要投资逻辑。周期视角来看，在市场化 亏损以及行政去产能合力下，2025年第四季度以及2026年上半年产能去化或呈现加速态势，2026年猪价 或震荡上行。此外，畜禽产业链上持续推荐经营能力领先、穿越周期的公司。种子种植领域推荐品种资 源优势强劲的公司。成长视角来看，宠物板块国内需求稳健，国货势头强劲，2026H2或继续迎业绩高 增。果蔬种植方面，预计蓝莓红利仍将持续。重点推荐种植面积持续增长、种植效率持续提升、品牌和 渠道持续进步、出海节奏加快的蓝莓龙头。功能糖领域迎超级代糖大单品。 ...

11月17日，保龄宝（证券代码：002286）发布公告，公司董事会于当日收到公司董事长戴斯觉的书面辞 职报告。戴斯觉因个人原因申请辞去公司董事长、董事、董事会战略委员会主任委员职务。 公告显示，截至本公告披露日，戴斯觉未直接持有公司股份，通过北京永裕投资管理有限公司持有公司 29508653股股票，占公司总股本的7.75%，戴斯觉为公司实际控制人之一。 中国执行信息公开网显示，戴斯觉控股的北京永裕投资管理有限公司，2025年9月，北京永裕投资管理 有限公司被江西银行股份有限公司南昌红谷滩支行，列为失信被执行人，执行标的金额为2.53亿元。 | 失信被执行人 | | --- | | 被执行人姓名/名称:北京永裕投资管理有限公司 | | 静砂性号器/用药机构代码: 9111010530 *** 280p | | 执行法院: 江西省南昌市中级人民法院 | | 省份: 江西 | | 执行体报文号: (2022) 赣01民机369号 | | 立案时间:2025年06月19日 | | 案号: (2025) 赣01执佐186号 | | 碳出执行体验单位: 江西省南昌市中级人民法院 | | 生效法律文书确定的义务: (202 ...

来源：每日经济新闻 "三十而立"的戴斯觉，选择在公司业绩强势反弹之际辞职。 11月17日晚间，保龄宝（002286.SZ，股价10.86元，市值40.64亿元）突发公告，公司董事会于11月17日 收到公司董事长戴斯觉的书面辞职报告。 彼时，戴斯觉年仅26岁，而保龄宝是功能糖龙头企业，他接手的时点，正值无糖饮料带动的赤藓糖醇行 业风口。凭借与元气森林等"网红气泡水"的合作，赤藓糖醇成为市场爆款。然而，戴斯觉在任期内很快 便经历了行业周期性变动的挑战。 2023年，赤藓糖醇行业因新玩家涌入导致产能激增，随即陷入了严重的供需失衡和价格战。紧接着， 2023年11月，欧盟委员会决定对原产于中国的赤藓糖醇产品发起反倾销调查。 戴斯觉任期内完整地经历了行业从高热到寒冬的"过山车"。不过，从业绩上看，保龄宝展现了穿越周期 的韧性。 《每日经济新闻》记者注意到，戴斯觉出生于1995年1月，在2021年3月接棒时年仅26岁，一度刷新A股 市场最年轻董事长的纪录。 戴斯觉此次辞任距其上任约四年半，他接手于"无糖风口"的鼎盛时期，随后经历了行业周期性波动和欧 盟反倾销调查的严峻挑战。 值得注意的是，尽管保龄宝在2024年及2025 ...

Core Viewpoint - The resignation of Dai Sijue, the chairman of Baolingbao, comes at a time of strong performance recovery for the company, raising questions about underlying financial pressures within the controlling shareholder's structure [5][6]. Company Overview - Baolingbao's stock price was reported at 10.86 yuan, with a market capitalization of 4.064 billion yuan as of November 17 [2]. - Dai Sijue, born in January 1995, became the youngest chairman in A-share market history at the age of 26 in March 2021 [3][6]. - His tenure lasted approximately four and a half years, during which he faced significant challenges, including industry fluctuations and an EU anti-dumping investigation [4][6]. Performance Analysis - Despite the challenges, Baolingbao demonstrated resilience, achieving a net profit of 111 million yuan in 2024, a year-on-year increase of 105.97%, and a significant rise in net profit excluding non-recurring items by 254.56% [8]. - For the first three quarters of 2025, the company reported revenue of 2.126 billion yuan, up 15.98%, and a net profit of 134 million yuan, reflecting a 32.58% increase year-on-year [8]. Shareholder Dynamics - The actual control of Baolingbao shifted in August 2024 from Dai Sijue alone to a joint control structure with his brother, Dai Sicong [10]. - A planned share buyback by the new controlling entity has faced delays due to "funding arrangements," with the initial commitment to increase holdings by 5% not being met [11][12]. - As of the resignation announcement, Dai Sijue held 29.5087 million shares through his investment firm, representing 7.75% of the total shares [13].

Core Viewpoint - The resignation of Dai Sijue, the youngest chairman in A-share history, comes at a time when the company, Baolingbao, is experiencing a strong performance rebound, raising questions about underlying pressures within the company's control structure [1][2][3] Company Performance - Baolingbao reported a net profit of 111 million yuan for 2024, a year-on-year increase of 105.97%, and a significant increase in non-recurring net profit by 254.56% [3] - For the first three quarters of 2025, Baolingbao achieved a revenue of 2.126 billion yuan, up 15.98% year-on-year, and a net profit of 134 million yuan, reflecting a 32.58% increase [3] Industry Context - The erythritol industry faced severe supply-demand imbalances and price wars in 2023 due to an influx of new players, followed by an anti-dumping investigation by the European Union [3] - The company has shown resilience in navigating the industry's cyclical challenges, focusing on high-value products and optimizing supply chain management [3] Control Structure Changes - The actual control of Baolingbao shifted from Dai Sijue alone to a joint control with his brother, Dai Sicong, in August 2024 [5] - A promised share buyback plan by the new controlling entity has faced delays, with the initial commitment to increase holdings by 5% not being fulfilled as of the latest reports [6] Financial Pressures - Dai Sijue's controlling entity, Yongyu Investment, has faced significant financial pressures, being listed as an executor in multiple court cases with total amounts exceeding 280 million yuan [1][6] - As of the resignation announcement, Dai Sijue held 7.75% of Baolingbao's shares through Yongyu Investment, indicating ongoing involvement despite his resignation [6]

每经记者｜彭斐 每经编辑｜张益铭 "三十而立"的戴斯觉，选择在公司业绩强势反弹之际辞职。 辞职背后，保龄宝实控人层面的资金压力隐现。就在2024年，保龄宝变更为由戴斯觉、戴斯聪兄弟共同 控制，而由戴斯聪控制的企业所承诺的增持计划，因"资金安排"原因一再拖延。与此同时，戴斯觉本人 控制的控股股东北京永裕投资管理有限公司（以下简称"永裕投资"），年内已多次被列为被执行人，涉 及金额超2.8亿元。 曾经的A股"最年轻董事长"谢幕 根据保龄宝11月17日晚间的公告，戴斯觉因个人原因申请辞去公司董事长、董事、董事会战略委员会主 任委员职务。 公告称，戴斯觉的辞职不会导致公司董事会成员低于法定最低人数，辞职报告自送达董事会时生效。辞 职后，他仍将担任公司全资孙公司BLB INTERNATIONAL DEVELOPMENT(SINGAPORE)PTE.ITD.、 BLB BIO-TECH USA INC董事职务。 戴斯觉的"A股最年轻董事长"身份始于2021年。资料显示，戴斯觉出生于1995年1月，为中国香港居 民，拥有英国曼彻斯特大学金融经济学理学硕士学历。2021年3月25日，保龄宝召开第五届董事会第一 次会议，会议以 ...

Core Viewpoint - The report from Huaxi Securities indicates that Baolingbao's Q3 2025 revenue, net profit attributable to shareholders, and net profit excluding non-recurring items were 727 million, 41 million, and 34 million yuan respectively, showing year-on-year growth of 12.23%, 30.21%, and 11.72% [1] Group 1: Financial Performance - Baolingbao's significant revenue growth is attributed to the substantial increase in sales of core products such as sugar-reducing sweeteners, prebiotics, and dietary fibers [1] - The improvement in gross margin is due to cost reduction and efficiency enhancement, alongside the increasing revenue share from core products [1] Group 2: Market Position and Product Strategy - As a leading enterprise in the domestic functional sugar industry, Baolingbao holds a significant market share in sugar-reducing sweeteners, prebiotics, and dietary fibers, supported by its comprehensive product layout and technological advantages [1] Group 3: Future Outlook - Short-term: With the new corn harvest in major production areas, corn prices are expected to remain low in Q4, which, combined with production cost reductions, may further enhance the gross margin of core products [1] - Mid-term: The accelerated approval process for allulose in China is expected to open up the domestic market, with Baolingbao's 20,000-ton expansion project already initiated, aiming for an annual capacity of approximately 30,000 tons by the end of 2026 [1] - Long-term: The launch of new high-value-added products such as HMOs (human milk oligosaccharides), algal oil DHA, and sugar-free resistant dextrin will further optimize the company's profit structure [1]